Trial intelligence / Profile preview

Tocilizumab versus placebo for infarct growth after endovascular thrombectomy in acute ischemic stroke

2025-521269-28-00Phase 2Authorised

Sponsor: Oslo University Hospital
Start: Mar 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 2

Overview

Phase 2, randomised, double-blind trial in ischemic stroke comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Delta DWI lesion volume. Planned start Mar 2026; status: authorised.

Drugs

tocilizumab

Conditions

ischemic stroke

Beyond the preview

Go deeper on 2025-521269-28-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-521269-28-00.